Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
TRACON Pharmaceuticals, Inc. (TCON)
OTHER OTC:TCON
RESEARCH TOOLSreports
TRACON Pharmaceuticals (TCON) Stock Price & Analysis
701 Followers
TCON Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.66 - $14.74
Previous Close$1.11
Volume118.28K
Average Volume (3M)239.57K
Market Cap
$2.97M
Enterprise Value-$4.92M
Total Cash (Recent Filing)$7.89M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)1.7
Beta1.09
Next Earnings
Aug 07, 2024EPS Estimate
-$1.05Last Dividend Ex-Date
Jun 27, 2024Dividend YieldN/A
Share Statistics
EPS (TTM)0.65
Shares Outstanding2,679,035
10 Day Avg. Volume281,146
30 Day Avg. Volume239,568
Standard Deviation0.41
R-Squared0.03
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)-1.90
Price to Sales (P/S)0.28
Price to Cash Flow (P/CF)-0.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-0.40
Enterprise Value/Gross Profit-0.41
Enterprise Value/Ebitda-0.39
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering2
TRACON Pharmaceuticals News
PremiumCompany Announcements
TRACON Pharmaceuticals Announces Executive Officer Resignation
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe ongoing P2 pivotal ENVASARC trial has made considerable progress with enrollment complete and updated response data along with a positive IDMC review.
Drug Market PotentialAnalyst reiterates a Buy rating with a revised price target to $55 post-reverse stock split.
Drug SafetyEnvafolimab continues to be well-tolerated with no serious drug-related adverse events.
Bears Say
Clinical DevelopmentTRACON announced that it will discontinue all of the company’s clinical development activities and will focus on reducing cash burn.
Financial PerformanceThe price target is being reduced to $6 from $20 due to expectations of additional dilution associated with future capital raises.
Market EntryThe anticipated market entry for envafolimab has been delayed to a later year.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
TCON FAQ
What was TRACON Pharmaceuticals, Inc.’s price range in the past 12 months?
TRACON Pharmaceuticals, Inc. lowest stock price was $0.66 and its highest was $14.74 in the past 12 months.
What is TRACON Pharmaceuticals, Inc.’s market cap?
Currently, no data Available
When is TRACON Pharmaceuticals, Inc.’s upcoming earnings report date?
TRACON Pharmaceuticals, Inc.’s upcoming earnings report date is Aug 07, 2024 which is in 35 days.
How were TRACON Pharmaceuticals, Inc.’s earnings last quarter?
TRACON Pharmaceuticals, Inc. released its earnings results on May 14, 2024. The company reported -$1.33 earnings per share for the quarter, missing the consensus estimate of -$1.19 by -$0.14.
Is TRACON Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts TRACON Pharmaceuticals, Inc.’s price is currently Overvalued.
Does TRACON Pharmaceuticals, Inc. pay dividends?
TRACON Pharmaceuticals, Inc. pays a Notavailable dividend of $0.04 which represents an annual dividend yield of N/A. See more information on TRACON Pharmaceuticals, Inc. dividends here
What is TRACON Pharmaceuticals, Inc.’s EPS estimate?
TRACON Pharmaceuticals, Inc.’s EPS estimate is -$1.05.
How many shares outstanding does TRACON Pharmaceuticals, Inc. have?
TRACON Pharmaceuticals, Inc. has 2,679,035 shares outstanding.
What happened to TRACON Pharmaceuticals, Inc.’s price movement after its last earnings report?
TRACON Pharmaceuticals, Inc. reported an EPS of -$1.33 in its last earnings report, missing expectations of -$1.19. Following the earnings report the stock price went down -17.766%.
Which hedge fund is a major shareholder of TRACON Pharmaceuticals, Inc.?
Among the largest hedge funds holding TRACON Pharmaceuticals, Inc.’s share is ETF Portfolio Partners, Inc.. It holds TRACON Pharmaceuticals, Inc.’s shares valued at 11K.
---
TRACON Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
― (―)
― (―)
Blogger Sentiment
Neutral
TCON Sentiment 50%
Sector Average 72%
Sector Average 72%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.7%
Last 30 Days ▲ 4.5%
Last 30 Days ▲ 4.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-80.92%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
12.40%
Trailing 12-Months
Company Description
TRACON Pharmaceuticals, Inc.
TRACON Pharmaceuticals, Inc. engages in the development and commercialization of targeted therapies for cancer, ophthalmic, and fibrotic diseases. Its products include TRC105, an anti-endoglin antibody for the treatment of solid tumor types; TRC205 created for the treatment of fibrotic diseases; and TRC102, a small molecule that is in clinical development made for lung cancer and glioblastoma. The company was founded in October 2004 and is headquartered in San Diego, CA.
---
TCON Earnings Call
Q1 2024
0:00 / 0:00
---
TCON Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Best Analysts Covering TCON
1 Year
1 Year Success Rate
0/8 ratings generated profit
1 Year Average Return
-74.59%
reiterated a buy rating 2 months ago
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -74.59% per trade.
---